Navigation Links
Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Date:3/20/2008

PRINCETON, N.J., March 20 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) today announced that it has received a milestone payment of an undisclosed amount from its licensing partner, Centocor, Inc., for the submission of a Marketing Authorization Application to the European Medicines Agency requesting approval of golimumab (CNTO 148) for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis.

Golimumab is a human anti-TNF monoclonal antibody that was generated by Medarex's UltiMAb Human Antibody Development System. Medarex may receive future milestone payments and royalties should this product candidate progress to commercialization and achieve commercial sales.

"We are excited by this regulatory filing for approval of a fully human antibody developed by Medarex's technology, and we are pleased by the advancements that Centocor continues to make with these antibodies," said Howard H. Pien, President and CEO of Medarex. "We have seen the accomplishment of a number of development milestones for UltiMAb antibodies -- both by our partners and by Medarex -- and look ahead to similar accomplishments that we believe will lead to important medicines to address underserved medical needs."

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.

Medarex Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed herein may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "expect"; "may"; or similar statements are forward- looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product development, unforeseen safety issues resulting from the administration of antibody products in humans, uncertainties concerning Centocor's activities under its agreement with Medarex, as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its quarterly reports on Form 10-Q. There can be no assurance that future milestone payments will be paid, whether the product development efforts will succeed, or whether other developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
2. Medarex to Present at the Susquehanna Financial Group Healthcare Conference
3. Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008
4. Medarex Announces Completion of Sale of Shares in Genmab A/S
5. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
6. Medarex Announces Election of Marc Rubin as New Board Member
7. Medarex to Present at the UBS Global Life Sciences Conference
8. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
9. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
10. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
11. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/17/2017)... ... August 17, 2017 , ... ... news outlet had provided a research update on Aytu Bioscience and cited promising ... , According to Soulstring, prescription rates for Natesto® have more than doubled since ...
(Date:8/16/2017)... ... August 16, 2017 , ... While art and science ... more closely connected than one might think. A Mesh Is Also a Snare, ... the University City Science Center’s Esther Klein Gallery (EKG) on August 17 and run ...
(Date:8/15/2017)... , Aug. 15, 2017 After spending the past ... support with crowdsourced data collection, GeneFo now offers this platform to ... aligning and amplifying support, adherence, and data collection vis a vis ... foundations mark the successful launch of this offer. ... GeneFo ...
(Date:8/15/2017)... ... 2017 , ... Kenall, a leader in sealed solid-state lighting, ... sealed and perform efficiently for years. The downlights are ideal for a variety ... such as: hospitals; behavioral health facilities; cleanrooms; containment areas; food and pharmaceutical processing ...
Breaking Biology Technology:
(Date:6/30/2017)... , June 30, 2017 Today, American ... and supplier of face and eye tracking software, ... Product provider program. "Artificial intelligence ... way to monitor a driver,s attentiveness levels while ... being able to detect fatigue and prevent potential ...
(Date:5/23/2017)... robotic gym for the rehabilitation and functional motor sense evaluation of lower ... . The first 30 robots will be available from June in ... The technology was developed and patented at the IIT laboratories and has ... to a 10 million euro investment from entrepreneur Sergio Dompè. ... ...
(Date:5/6/2017)... May 5, 2017 RAM Group ... a new breakthrough in biometric authentication based on ... mechanical properties to perform biometric authentication. These new sensors ... material created by Ram Group and its partners. This ... transportation, supply chains and security. Ram Group is ...
Breaking Biology News(10 mins):